Ong Sandy Gim Ming, Ming Long Chiau, Lee Kah Seng, Yuen Kah Hay
School of Pharmaceutical Sciences, Universiti of Sains Malaysia, 11800 Penang, Malaysia.
Unit for Medication Outcomes Research and Education (UMORE), Pharmacy, School of Medicine, University of Tasmania, 7001 Hobart, Australia.
Pharmaceutics. 2016 Aug 26;8(3):25. doi: 10.3390/pharmaceutics8030025.
The objective of the present study was to investigate the influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Griseofulvin-loaded liposomes with desired characteristics were prepared from pro-liposome using various techniques. To study the effect of encapsulation efficiency, three preparations of griseofulvin, namely, griseofulvin aqueous suspension and two griseofulvin-loaded liposomes with different amounts of griseofulvin encapsulated [i.e., F1 (32%) and F2(98%)], were administered to rats. On the other hand, to study the effect of liposome size, the rats were given three different griseofulvin-loaded liposomes of various sizes, generated via different mechanical dispersion techniques [i.e., FTS (142 nm), MS (357 nm) and NS (813 nm)], but with essentially similar encapsulation efficiencies (about 93%). Results indicated that the extent of bioavailability of griseofulvin was improved 1.7-2.0 times when given in the form of liposomes (F1) compared to griseofulvin suspension. Besides that, there was an approximately two-fold enhancement of the extent of bioavailability following administration of griseofulvin-loaded liposomes with higher encapsulation efficiency (F2), compared to those of F1. Also, the results showed that the extent of bioavailability of liposomal formulations with smaller sizes were higher by approximately three times compared to liposomal formulation of a larger size. Nevertheless, a further size reduction of griseofulvin-loaded liposome (≤400 nm) did not promote the uptake or bioavailability of griseofulvin. In conclusion, high drug encapsulation efficiency and small liposome size could enhance the oral bioavailability of griseofulvin-loaded liposomes and therefore these two parameters deserve careful consideration during formulation.
本研究的目的是探讨脂质体的包封率和粒径对灰黄霉素脂质体口服生物利用度的影响。采用多种技术由前体脂质体制备具有所需特性的灰黄霉素脂质体。为研究包封率的影响,将三种灰黄霉素制剂,即灰黄霉素水混悬液和两种包封不同量灰黄霉素的脂质体[即F1(32%)和F2(98%)]给予大鼠。另一方面,为研究脂质体粒径的影响,给大鼠给予三种通过不同机械分散技术制备的不同粒径的灰黄霉素脂质体[即FTS(142nm)、MS(357nm)和NS(813nm)],但其包封率基本相似(约93%)。结果表明,与灰黄霉素混悬液相比,以脂质体(F1)形式给予时,灰黄霉素的生物利用度提高了1.7 - 2.0倍。除此之外,与F1相比,给予包封率较高的灰黄霉素脂质体(F2)后,生物利用度提高了约两倍。此外,结果显示,较小粒径脂质体制剂的生物利用度相比较大粒径脂质体制剂提高了约三倍。然而,进一步减小灰黄霉素脂质体的粒径(≤400nm)并未促进灰黄霉素的摄取或生物利用度。总之,高药物包封率和小脂质体粒径可提高灰黄霉素脂质体的口服生物利用度,因此在制剂过程中这两个参数值得仔细考虑。